Login to Your Account

Positive pivotal data for Trophos’ olesoxime in SMA; filings up next

By Jennifer Boggs
Managing Editor

Monday, March 10, 2014
Patients with spinal muscular atrophy (SMA) and their families, who rejoiced two weeks ago when Isis Pharmaceuticals Inc. posted positive phase Ia/IIb data with its antisense candidate, got even better news Monday: French biopharma Trophos SA scored positive pivotal results with neuroprotective candidate olesoxime, putting it on track to file what could become the first treatment specifically for SMA.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription